The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers

The dual tyrosine kinase (EGFR/HER2) inhibitor lapatinib is currently used to clinically treat HER2-positive breast cancer. However, a majority of patients do not respond to lapatinib therapy within 6 months. Therefore, potentiating the anti-tumor effect of lapatinib by combination treatment has a g...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Ziyin, Yang, Yan, Wu, He, Chen, Yongye, Jia, Hao, Zhu, Lei, He, Runjia, Jin, Yibo, Zhou, Bei, Ge, Chunpo, Sun, Yanxia, Yang, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449760/
https://www.ncbi.nlm.nih.gov/pubmed/36090218
http://dx.doi.org/10.1016/j.heliyon.2022.e10410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449760/
https://www.ncbi.nlm.nih.gov/pubmed/36090218
http://dx.doi.org/10.1016/j.heliyon.2022.e10410

Ejemplares similares